Johanna Friedl-Naderer

Insider Reports History

Location
C/O Vir Biotechnology, Inc., 499 Illinois Street, Suite 500, San Francisco, CA
Signature
/s/ Ron Caponigro, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Johanna Friedl-Naderer:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Dyne Therapeutics, Inc. Chief Commercial Officer Common Stock 94.9K $1.27M $13.41 Sep 5, 2025 Direct
Vir Biotechnology, Inc. EVP & Chief Operating Officer Common Stock 149K $227K $1.53 Mar 3, 2023 Direct
Vir Biotechnology, Inc. EVP & Chief Operating Officer Stock Option (Right to Buy) 70K $107K $1.53 Feb 22, 2023 Direct
Dyne Therapeutics, Inc. Chief Commercial Officer Stock option (right to buy) 51.3K Jul 16, 2025 Direct

Insider Reports Filed by Johanna Friedl-Naderer

Symbol Company Period Transactions Value $ Form Type Date Filed Role
DYN Dyne Therapeutics, Inc. Sep 4, 2025 2 -$13.8K 4 Sep 8, 2025 Chief Commercial Officer
DYN Dyne Therapeutics, Inc. Jul 16, 2025 1 $0 4 Jul 18, 2025 Chief Commercial Officer
DYN Dyne Therapeutics, Inc. Jun 5, 2025 1 -$1.95K 4 Jun 6, 2025 Chief Commercial Officer
DYN Dyne Therapeutics, Inc. Mar 13, 2025 1 -$1.73K 4 Mar 13, 2025 Chief Commercial Officer
DYN Dyne Therapeutics, Inc. Dec 4, 2024 2 $0 4 Dec 6, 2024 Chief Commercial Officer
DYN Dyne Therapeutics, Inc. Sep 3, 2024 0 $0 3 Sep 3, 2024 Chief Commercial Officer
DYN Dyne Therapeutics, Inc. Sep 3, 2024 2 $0 4 Sep 3, 2024 Chief Commercial Officer
VIR Vir Biotechnology, Inc. Mar 3, 2023 1 -$33.8K 4 Mar 7, 2023 EVP & Chief Operating Officer
VIR Vir Biotechnology, Inc. Feb 22, 2023 2 $0 4 Feb 24, 2023 EVP & Chief Operating Officer
VIR Vir Biotechnology, Inc. Mar 2, 2022 2 $0 4 Mar 8, 2022 Chief Business Officer, Global
VIR Vir Biotechnology, Inc. Mar 2, 2022 0 $0 3 Mar 8, 2022 Chief Business Officer, Global